Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 31;13(4):375-385.
doi: 10.1515/jtim-2025-0032. eCollection 2025 Aug.

DEK-NUP214 monitoring before and after allogeneic haematopoietic stem cell transplantation for acute myeloid leukemia: A report from the TROPHY study group

Shuang Fan  1 , Yang Yang  2 , Shengye Lu  1 , Jiayu Huang  3   4 , Xiaosu Zhao  1   5 , Yang Cao  2 , Xiaodong Mo  1   5 , Xiaoxia Hu  3   4
Affiliations

DEK-NUP214 monitoring before and after allogeneic haematopoietic stem cell transplantation for acute myeloid leukemia: A report from the TROPHY study group

Shuang Fan et al. J Transl Int Med. .

Abstract

Background and objectives: Acute myeloid leukaemia (AML) with the translocation of chromosome (6;9)(p23;q34) forms the DEK-NUP214 fusion mRNA, which is a rare subtype (~1%). Owing to the paucity of this AML subtype, comprehensive studies analysing allogeneic haematopoietic stem cell transplantation (allo-HSCT) outcomes are lacking.

Methods: We aimed to evaluate the dynamic evolution of DEK-NUP214 transcripts before and after allo-HSCT as well as the impact of pretransplant DEK-NUP214 status on posttransplant outcomes in AML patients in a retrospective, multicentre study (n = 14).

Results: Intermediate- or high-risk AML patients without DEK-NUP214 transcripts receiving allo-HSCT during the same time period were enrolled as controls. Ten (71.4%) patients showed DEK-NUP214 positivity before allo-HSCT. Except for one patient who died early after allo-HSCT, 7 out of the other 9 patients (77.8%) achieved DEK-NUP214 negativity after allo-HSCT. The 2-year probabilities of relapse, non-relapse mortality (NRM), leukaemia-free survival (LFS), and overall survival (OS) were 14.3% (95% CI, 0%-33.6%), 35.7% (95% CI, 9.3%-62.1%), 50.0% (95% CI, 29.6%-84.4%), and 50.0% (95% CI, 29.6%-84.4%), respectively. The incidence of relapse was comparable between AML patients with and without DEK-NUP214 transcript, but the incidence of NRM, LFS, and OS of patients with DEK-NUP214 was poorer compared with those without DEK-NUP214 transcript.

Conclusions: Thus, this study observed that allo-HSCT could overcome the poor prognosis of persistent DEK-NUP214 positivity after chemotherapy; however, new therapies should be further identified to improve the outcomes of AML patients with DEK-NUP214.

Keywords: DEK-NUP214 transcript; acute myeloid leukaemia; allogeneic haematopoietic stem cell transplantation; retrospective study.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest The authors declare no competing interests.

Figures

None
Graphical abstract
Figure 1
Figure 1
The distribution of partner genes for DEK-NUP214 (A) and types of other molecular abnormalities (B).
Figure 2
Figure 2
The 2-year probability of clinical outcomes after allo-HSCT, relapse (A), nonrelapse mortality (B), leukaemia-free survival (C), and overall survival (D).
Figure 3
Figure 3
The 2-year probability of clinical outcomes after allo-HSCT according to patients with and without DEK-NUP214 transcript, relapse (A), non-relapse mortality (B), leukaemia-free survival (C), and overall survival (D).
See this image and copyright information in PMC

References

    1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937. et al. - - PubMed
    1. Slovak ML, Gundacker H, Bloomfield CD, Dewald G, Appelbaum FR, Larson RA. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare ‘poor prognosis’ myeloid malignancies. Leukemia. 2006;20:1295. et al. - - PubMed
    1. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354. et al. - - PubMed
    1. Tarlock K, Alonzo TA, Moraleda PP, Gerbing RB, Raimondi SC, Hirsch BA. Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children’s Oncology Group. Br J Haematol. 2014;166:254. et al. - - PMC - PubMed
    1. Garçon L, Libura M, Delabesse E, Valensi F, Asnafi V, Berger C. DEK-CAN molecular monitoring of myeloid malignancies could aid therapeutic stratification. Leukemia. 2005;19:1338. et al. - - PubMed

LinkOut - more resources